These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39073345)

  • 21. Structural insights into the role and targeting of EGFRvIII.
    Bagchi A; Stayrook SE; Xenaki KT; Starbird CA; Doulkeridou S; El Khoulati R; Roovers RC; Schmitz KR; van Bergen En Henegouwen PMP; Ferguson KM
    Structure; 2024 Sep; 32(9):1367-1380.e6. PubMed ID: 38908376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL
    Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
    Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
    Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FHL2 interacts with EGFR to promote glioblastoma growth.
    Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
    Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
    Zhan Y; Counelis GJ; O'Rourke DM
    Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR; Boskovitz A; Kuan CT; Pegram CN; Ayriss J; Wikstrand CJ; Buckley AF; Lipp ES; Herndon JE; McLendon RE; Bigner DD
    Nucl Med Biol; 2012 Jan; 39(1):23-34. PubMed ID: 21958852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading.
    Jubran MR; Rubinstein AM; Cojocari I; Adejumobi IA; Mogilevsky M; Tibi S; Sionov RV; Verreault M; Idbaih A; Karni R; Kravchenko-Balasha N
    Oncogenesis; 2020 Feb; 9(2):11. PubMed ID: 32024816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells.
    Choi D; Montermini L; Kim DK; Meehan B; Roth FP; Rak J
    Mol Cell Proteomics; 2018 Oct; 17(10):1948-1964. PubMed ID: 30006486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells.
    Sangar V; Funk CC; Kusebauch U; Campbell DS; Moritz RL; Price ND
    Mol Cell Proteomics; 2014 Oct; 13(10):2618-31. PubMed ID: 24997998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Temozolomide Induces Endocytosis of EGFRvIII via p38-Mediated Non-canonical Phosphorylation in Glioblastoma Cells.
    Haryuni RD; Tanaka T; Takahashi JI; Onuma I; Zhou Y; Yokoyama S; Sakurai H
    Biol Pharm Bull; 2021; 44(11):1681-1687. PubMed ID: 34719645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
    Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
    Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
    Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells.
    Cetin MH; Rieckmann T; Hoffer K; Riepen B; Christiansen S; Gatzemeier F; Feyerabend S; Schoof M; Schüller U; Petersen C; Mynarek M; Rothkamm K; Kriegs M; Struve N
    Radiat Oncol; 2023 Jan; 18(1):19. PubMed ID: 36709315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma.
    Yeo AT; Jun HJ; Appleman VA; Zhang P; Varma H; Sarkaria JN; Charest A
    Oncogene; 2021 Apr; 40(15):2682-2696. PubMed ID: 33707748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFRvIII-mediated radioresistance through a strong cytoprotective response.
    Lammering G; Hewit TH; Valerie K; Contessa JN; Amorino GP; Dent P; Schmidt-Ullrich RK
    Oncogene; 2003 Aug; 22(36):5545-53. PubMed ID: 12944901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer.
    Denholt CL; Binderup T; Stockhausen MT; Poulsen HS; Spang-Thomsen M; Hansen PR; Gillings N; Kjær A
    Nucl Med Biol; 2011 May; 38(4):509-15. PubMed ID: 21531288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.